

Peter C Black

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3793733/publications.pdf>

Version: 2024-02-01

452
papers

13,533
citations

19636

61
h-index

32815

100
g-index

462
all docs

462
docs citations

462
times ranked

13984
citing authors

#	ARTICLE	IF	CITATIONS
1	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
2	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	0.9	638
3	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018, 74, 784-795.	0.9	530
4	Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. <i>PLoS ONE</i> , 2013, 8, e66855.	1.1	524
5	Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. <i>Journal of Urology</i> , 2013, 190, 2047-2053.	0.2	280
6	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	0.8	268
7	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	0.9	235
8	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
9	The impact of variant histology on the outcome of bladder cancer treated with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 3-7.	0.8	211
10	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	0.9	211
11	Enhanced recovery after surgery (ERAS) protocols: Time to change practice?. <i>Canadian Urological Association Journal</i> , 2011, 5, 342-348.	0.3	199
12	Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments. <i>Lab on A Chip</i> , 2014, 14, 32-44.	3.1	175
13	Differences in Survival Among Patients With Sarcomatoid Carcinoma, Carcinosarcoma and Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2007, 178, 2302-2307.	0.2	146
14	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
15	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	0.9	131
16	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	0.9	128
17	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
18	Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets. <i>Small</i> , 2016, 12, 1909-1919.	5.2	122

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	3.2	121
20	Morphological Differences between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e85264.	1.1	119
21	Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts. <i>Medical Image Analysis</i> , 2018, 50, 167-180.	7.0	114
22	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018, 73, 738-748.	0.9	112
23	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 59-68.	0.9	112
24	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020, 78, 893-906.	0.9	112
25	Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 623-634.	2.7	107
26	Evasion of immunosurveillance by genomic alterations of PPAR β /RXR α in bladder cancer. <i>Nature Communications</i> , 2017, 8, 103.	5.8	107
27	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2017, 197, 135-142.	0.2	106
28	MESHED UNEXPANDED SPLIT-THICKNESS SKIN GRAFTING FOR RECONSTRUCTION OF PENILE SKIN LOSS. <i>Journal of Urology</i> , 2004, 172, 976-979.	0.2	102
29	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020, 26, 882-891.	3.2	98
30	Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. <i>BJU International</i> , 2013, 111, 946-953.	1.3	97
31	Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 1478-1486.	3.2	96
32	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 53-59.	0.2	95
33	A Prospective Randomized Trial of Povidone-Iodine Prophylactic Cleansing of the Rectum Before Transrectal Ultrasound Guided Prostate Biopsy. <i>Journal of Urology</i> , 2013, 189, 1326-1331.	0.2	92
34	Deep Learning-Based Gleason Grading of Prostate Cancer From Histopathology Images—Role of Multiscale Decision Aggregation and Data Augmentation. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 1413-1426.	3.9	89
35	Underutilization of local salvage therapy after radiation therapy for prostate cancer Funding: UBC Summer Student Research Program.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 701-706.	0.8	86
36	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. <i>Scientific Reports</i> , 2017, 7, 42713.	1.6	85

#	ARTICLE	IF	CITATIONS
37	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021, 12, 184.	5.8	85
38	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5082-5093.	3.2	82
39	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. <i>Journal of Clinical Oncology</i> , 2019, 37, 3090-3098.	0.8	81
40	Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer. <i>Journal of Urology</i> , 2008, 179, 353-358.	0.2	80
41	<i>Kdm6a</i> Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with <i>p53</i> Dysfunction. <i>Clinical Cancer Research</i> , 2020, 26, 2065-2079.	3.2	80
42	Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1245-1254.	1.9	79
43	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78
44	Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 2981-2992.	3.2	78
45	Targeted therapies in bladder cancer— an update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 433-438.	0.8	77
46	Prostate Cancer on the Internet—Information or Misinformation?. <i>Journal of Urology</i> , 2006, 175, 1836-1842.	0.2	74
47	Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. <i>Prostate</i> , 2007, 67, 743-756.	1.2	74
48	Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps. <i>Lab on A Chip</i> , 2015, 15, 2278-2286.	3.1	74
49	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020, 78, 719-730.	0.9	73
50	Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. <i>European Urology</i> , 2015, 67, 876-888.	0.9	72
51	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. <i>European Urology</i> , 2017, 71, 545-557.	0.9	72
52	Comparison of Artificial Intelligence Techniques to Evaluate Performance of a Classifier for Automatic Grading of Prostate Cancer From Digitized Histopathologic Images. <i>JAMA Network Open</i> , 2019, 2, e190442.	2.8	72
53	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?. <i>Journal of Urology</i> , 2016, 195, 886-893.	0.2	71
54	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 215-220.	1.2	71

#	ARTICLE	IF	CITATIONS
55	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	3.2	71
56	Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results from the GBD Study 2016. <i>Journal of Urology</i> , 2019, 201, 893-901.	0.2	71
57	Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5528-5535.	0.8	70
58	Urethral and Bladder Neck Injury Associated With Pelvic Fracture in 25 Female Patients. <i>Journal of Urology</i> , 2006, 175, 2140-2144.	0.2	69
59	Regulation of secretion of PTHrP by Ca ²⁺ -sensing receptor in human astrocytes, astrocytomas, and meningiomas. <i>American Journal of Physiology - Cell Physiology</i> , 2000, 279, C691-C699.	2.1	68
60	Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting. <i>PLoS ONE</i> , 2013, 8, e57284.	1.1	68
61	CUA guidelines on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2015, 9, 690.	0.3	67
62	Fluoroquinolone Resistant Rectal Colonization Predicts Risk of Infectious Complications after Transrectal Prostate Biopsy. <i>Journal of Urology</i> , 2014, 192, 1673-1678.	0.2	65
63	Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. <i>Clinical Cancer Research</i> , 2021, 27, 5123-5130.	3.2	65
64	NEPHRON SPARING SURGERY FOR CENTRAL RENAL TUMORS: EXPERIENCE WITH 33 CASES. <i>Journal of Urology</i> , 2000, 163, 737-743.	0.2	64
65	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. <i>Journal of Urology</i> , 2015, 194, 1120-1131.	0.2	64
66	Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. <i>European Journal of Immunology</i> , 2017, 47, 385-393.	1.6	64
67	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. <i>BJU International</i> , 2007, 100, 1377-1384.	1.3	63
68	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. <i>BJU International</i> , 2016, 118, 855-863.	1.3	61
69	Luminal Water Imaging: A New MR Imaging T2 Mapping Technique for Prostate Cancer Diagnosis. <i>Radiology</i> , 2017, 284, 451-459.	3.6	61
70	Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aNOMO Bladder Cancer Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2018, 199, 1452-1458.	0.2	61
71	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 277-285.	1.9	60
72	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016, 94, 154-160.	0.5	60

#	ARTICLE	IF	CITATIONS
73	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal, 2016, 10, 46.	0.3	55
74	The Contemporary Role of Lymph Node Dissection During Nephroureterectomy in the Management of Upper Urinary Tract Urothelial Carcinoma: The Canadian Experience. Urology, 2012, 79, 840-845.	0.5	53
75	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. Molecular Cancer Therapeutics, 2018, 17, 2746-2755.	1.9	53
76	Theophylline Target Concentration in Severe Airways Obstruction - 10 or 20 mg/L?. Clinical Pharmacokinetics, 1993, 25, 495-505.	1.6	52
77	Non-“risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. European Urology, 2018, 73, 899-907.	0.9	51
78	Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal, 2018, 13, 230-238.	0.3	51
79	Multiparametric Magnetic Resonance Imaging Enhances Detection of Significant Tumor in Patients on Active Surveillance for Prostate Cancer. Urology, 2015, 85, 423-429.	0.5	50
80	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU International, 2013, 112, 791-797.	1.3	49
81	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 31.e17-31.e24.	0.8	49
82	Growth factors and receptors as prognostic markers in urothelial carcinoma. Current Urology Reports, 2008, 9, 55-61.	1.0	48
83	Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nature Reviews Urology, 2014, 11, 220-230.	1.9	48
84	Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective. Nature Reviews Urology, 2022, 19, 280-294.	1.9	48
85	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	46
86	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. European Urology Oncology, 2018, 1, 91-100.	2.6	46
87	Highly selective biomechanical separation of cancer cells from leukocytes using microfluidic ratchets and hydrodynamic concentrator. Biomicrofluidics, 2013, 7, 34114.	1.2	45
88	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration1Co-first authors.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 839-845.	0.8	44
89	Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer, 2018, 143, 1764-1773.	2.3	44
90	Using the Delphi Technique to Improve Clinical Outcomes Through the Development of Quality Indicators in Renal Cell Carcinoma. Journal of Oncology Practice, 2013, 9, e262-e267.	2.5	43

#	ARTICLE	IF	CITATIONS
91	Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach. <i>PLoS ONE</i> , 2013, 8, e59536.	1.1	43
92	Unravelling disparate roles of NOTCH in bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 345-357.	1.9	42
93	STRATEGIES FOR RECONSTRUCTION AFTER UNSUCCESSFUL OR UNSATISFACTORY PRIMARY TREATMENT OF PATIENTS WITH BLADDER EXSTROPHY OR INCONTINENT EPISPADIAS. <i>Journal of Urology</i> , 1999, 161, 1934-1941.	0.2	41
94	Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). <i>Canadian Urological Association Journal</i> , 2013, 7, 44.	0.3	41
95	Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 19-29.	0.2	41
96	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. <i>European Urology</i> , 2019, 76, 200-206.	0.9	41
97	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. <i>International Journal of Cancer</i> , 2014, 135, 939-947.	2.3	39
98	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. <i>Oncotarget</i> , 2015, 6, 21522-21532.	0.8	39
99	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , 2017, 72, 142-150.	0.9	38
100	Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. <i>European Urology Oncology</i> , 2020, 3, 622-630.	2.6	38
101	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e1-486.e7.	0.8	37
102	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1161-1165.	0.8	36
103	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2016, 196, 1627-1633.	0.2	36
104	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , 2019, 11, 60.	3.6	36
105	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>European Urology</i> , 2021, 79, 16-19.	0.9	36
106	Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. <i>BJU International</i> , 2010, 106, 1799-1804.	1.3	35
107	Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 165.e1-165.e7.	0.8	34
108	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 199, 1129-1142.	0.2	34

#	ARTICLE	IF	CITATIONS
109	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , 2016, 196, 1036-1041.	0.2	33
110	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017, 11, 182.	0.3	33
111	Penile Carcinoma: Lessons Learned from Vulvar Carcinoma. <i>Journal of Urology</i> , 2013, 189, 17-24.	0.2	32
112	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014, 8, 845.	0.3	32
113	Intraoperative Registered Transrectal Ultrasound Guidance for Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 193, 302-312.	0.2	32
114	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 413-422.	0.8	32
115	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718.	2.6	32
116	Neoadjuvant chemotherapy for bladder cancer. <i>World Journal of Urology</i> , 2006, 24, 531-542.	1.2	30
117	Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa. <i>Journal of Urology</i> , 2013, 190, 1404-1409.	0.2	30
118	MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 861-869.	1.9	30
119	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46.	0.9	30
120	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015, 116, 72-78.	1.3	29
121	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334.	0.8	29
122	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
123	Re: Aurélien Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2020;77:420-433. <i>European Urology</i> , 2020, 77, e105-e106.	0.9	29
124	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020, 3, 420-423.	2.6	29
125	Toward Real-Time Image Guided Neurosurgery Using Distributed and Grid Computing. , 2006, , .		28
126	Prognostic Significance of Body Mass Index in Asian Patients With Localized Renal Cell Carcinoma. <i>Nutrition and Cancer</i> , 2011, 63, 908-915.	0.9	28

#	ARTICLE	IF	CITATIONS
127	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Canadian Urological Association Journal, 2014, 8, 398.	0.3	28
128	Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 483.e9-483.e16.	0.8	28
129	Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 287-294.	0.8	28
130	Current Clinical Trials in Non-muscle Invasive Bladder Cancer. Current Urology Reports, 2018, 19, 101.	1.0	28
131	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. European Urology, 2020, 78, 387-399.	0.9	28
132	Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?. Current Opinion in Urology, 2006, 16, 344-349.	0.9	26
133	Receptor Heterodimerization: A New Mechanism for Platelet-Derived Growth Factor Induced Resistance to Anti-Epidermal Growth Factor Receptor Therapy for Bladder Cancer. Journal of Urology, 2011, 185, 693-700.	0.2	26
134	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 441-448.	0.8	26
135	A partial augmented reality system with live ultrasound and registered preoperative MRI for guiding robot-assisted radical prostatectomy. Medical Image Analysis, 2020, 60, 101588.	7.0	26
136	Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. Oncotarget, 2016, 7, 39980-39995.	0.8	26
137	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e17-486.e23.	0.8	25
138	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. European Urology Oncology, 2018, 1, 223-230.	2.6	25
139	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. American Journal of Surgical Pathology, 2019, 43, 1600-1610.	2.1	24
140	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. Journal of Urology, 2019, 202, 49-56.	0.2	24
141	Variant histology in bladder cancer: diagnostic and clinical implications. Translational Cancer Research, 2020, 9, 6565-6575.	0.4	23
142	Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy. Journal of Urology, 2019, 202, 1001-1007.	0.2	23
143	Cystoprostatectomy and neobladder construction for florid cystitis glandularis. Urology, 2005, 65, 174.	0.5	22
144	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	1.2	22

#	ARTICLE	IF	CITATIONS
145	Considerations on the use of diagnostic markers in management of patients with bladder cancer. World Journal of Urology, 2008, 26, 39-44.	1.2	21
146	CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatment Strategy for Bladder Cancer. Bladder Cancer, 2017, 3, 79-88.	0.2	21
147	Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. Lab on A Chip, 2018, 18, 1736-1749.	3.1	21
148	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patients undergoing urologic oncology surgery: a systematic review. World Journal of Urology, 2022, 40, 1325-1342.	1.2	21
149	Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e1-605.e8.	0.8	20
150	Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2019, 202, 1111-1119.	0.2	20
151	DHH is an Independent Prognosticator of Oncologic Outcome of Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1842-1848.	0.2	19
152	Statistical Biomechanical Surface Registration: Application to MR-TRUS Fusion for Prostate Interventions. IEEE Transactions on Medical Imaging, 2015, 34, 2535-2549.	5.4	19
153	Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU International, 2015, 116, 556-567.	1.3	19
154	Emerging role of checkpoint inhibition in localized bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 548-555.	0.8	19
155	Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).. Journal of Clinical Oncology, 2021, 39, 4541-4541.	0.8	19
156	Adenoviral Mediated Interferon- β Gene Therapy Suppresses the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Superficial Bladder Cancer. Journal of Urology, 2007, 177, 1900-1906.	0.2	18
157	Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Canadian Urological Association Journal, 2013, 7, 312.	0.3	18
158	Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy. World Journal of Urology, 2016, 34, 41-48.	1.2	18
159	Genomic Subtyping in Bladder Cancer. Current Urology Reports, 2020, 21, 9.	1.0	18
160	The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. Human Gene Therapy, 2019, 30, 44-56.	1.4	18
161	Extensive palliative surgery for advanced mesothelioma of the tunica vaginalis. Urology, 2003, 62, 748.	0.5	17
162	Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. Frontiers in Genetics, 2012, 3, 23.	1.1	17

#	ARTICLE	IF	CITATIONS
163	Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guérin and electromotive mitomycin versus bacillus Calmette-Guérin alone for patients with high-risk non-muscle-invasive bladder cancer. <i>Cancer</i> , 2014, 120, 2424-2431.	2.0	17
164	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	17
165	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.	0.9	17
166	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. <i>Cell Reports Medicine</i> , 2021, 2, 100382.	3.3	17
167	Keyhole Limpet Haemocyanin in Experimental Bladder Cancer. <i>European Urology</i> , 2000, 37, 34-40.	0.9	16
168	Clinical significance of ureteric "skip lesions" at the time of radical cystectomy: the M.D.A. Anderson experience and literature review. <i>BJU International</i> , 2014, 113, E28-33.	1.3	16
169	Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1051-1060.	0.8	16
170	Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018, 4, 512-521.	1.6	16
171	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 119-125.	2.6	16
172	Radical cystectomy: a review of techniques, developments and controversies. <i>Translational Andrology and Urology</i> , 2020, 9, 3073-3081.	0.6	16
173	Real-Time FEM-Based Registration of 3-D to 2.5-D Transrectal Ultrasound Images. <i>IEEE Transactions on Medical Imaging</i> , 2018, 37, 1877-1886.	5.4	15
174	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2018, 12, .	0.3	15
175	Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?. <i>European Urology Oncology</i> , 2019, 2, 597-602.	2.6	15
176	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	0.8	15
177	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
178	Next generation biomarkers in prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 328-342.	3.0	14
179	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 689-695.e2.	0.9	14
180	Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 858-866.	0.8	14

#	ARTICLE	IF	CITATIONS
181	The role of radical cystectomy in patients with clinical T4b bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 157-161.	0.8	13
182	Status of robotic-assisted surgery among Canadian urology residents. <i>Canadian Urological Association Journal</i> , 2012, 6, 160-167.	0.3	13
183	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 434-440.	1.3	13
184	Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study. <i>NMR in Biomedicine</i> , 2019, 32, e4048.	1.6	13
185	From Vision to Reality: The Origins of Intraoperative MR Imaging. <i>Acta Neurochirurgica Supplementum</i> , 2011, 109, 3-7.	0.5	13
186	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1015-1026.	1.1	12
187	A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12-months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. <i>BJU International</i> , 2007, 100, 63-69.	1.3	12
188	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309.	0.3	12
189	Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer. <i>JAMA Oncology</i> , 2016, 2, 855.	3.4	12
190	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. <i>Journal of Endourology</i> , 2017, 31, 645-650.	1.1	12
191	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2017, 24, 7-15.	0.5	12
192	Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 173.	0.3	12
193	Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator. <i>World Journal of Urology</i> , 2020, 38, 1215-1220.	1.2	12
194	Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward. <i>Canadian Urological Association Journal</i> , 2020, 14, 204-213.	0.3	12
195	Hand-assisted laparoscopic right-donor nephrectomy in a patient with situs inversus.. <i>Transplantation</i> , 2003, 76, 1530.	0.5	11
196	Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts. <i>Journal of Visualized Experiments</i> , 2014, , e51123.	0.2	11
197	Post-radiation epithelioid angiosarcoma of the urinary bladder and prostate. <i>Canadian Urological Association Journal</i> , 2016, 10, 197.	0.3	11
198	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 342.e7-342.e14.	0.8	11

#	ARTICLE	IF	CITATIONS
199	Sex- and age-related differences in the distribution of bladder cancer metastases. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 976-983.	0.6	11
200	Urinary Large Cell Neuroendocrine Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1399-1408.	2.1	11
201	Clinically Significant Urethral Stricture and/or Subclinical Urethral Stricture after High-Intensity Focused Ultrasound Correlates with Disease-Free Survival in Patients with Localized Prostate Cancer. <i>Urologia Internationalis</i> , 2011, 87, 276-281.	0.6	10
202	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 12, 243-251.	0.3	10
203	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	1.3	10
204	Prevalence of APC and PTEN Alterations in Urachal Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 2773-2781.	0.9	10
205	Evaluation of a marker-less, intra-operative, augmented reality guidance system for robot-assisted laparoscopic radical prostatectomy. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 1225-1233.	1.7	10
206	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	1.3	10
207	Recurrence and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification. <i>BJU International</i> , 2021, 127, 473-485.	1.3	10
208	Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110390.	1.4	10
209	Cystoenteric Conversion and Reduction Cystoplasty for Treatment of Bladder Dysfunction After Pancreas Transplantation. <i>Journal of Urology</i> , 2003, 170, 1913-1917.	0.2	9
210	Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma. <i>Urology</i> , 2016, 89, 8-9.	0.5	9
211	Orthotopic Mouse Models of Urothelial Cancer. <i>Methods in Molecular Biology</i> , 2018, 1655, 177-197.	0.4	9
212	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97.	0.3	9
213	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	9
214	Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis. <i>Current Molecular Pharmacology</i> , 2020, 13, 150-172.	0.7	9
215	Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. <i>Supportive Care in Cancer</i> , 2011, 19, 1117-1124.	1.0	8
216	Detection of Bladder Cancer Using Proteomic Profiling of Urine Sediments. <i>PLoS ONE</i> , 2012, 7, e42452.	1.1	8

#	ARTICLE	IF	CITATIONS
217	Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. Canadian Urological Association Journal, 2015, 9, 397.	0.3	8
218	Surgical Management of Stage T1 Renal Tumors in Canadian Academic Centers. Canadian Urological Association Journal, 2015, 9, 99.	0.3	8
219	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 469-476.	0.8	8
220	Dose dense MVAC prior to radical cystectomy: a real-world experience. World Journal of Urology, 2017, 35, 1729-1736.	1.2	8
221	Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer. International Journal of Urology, 2017, 24, 594-600.	0.5	8
222	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer, 2017, 3, 145-146.	0.2	8
223	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. Canadian Urological Association Journal, 2017, 11, 232-7.	0.3	8
224	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal, 2019, 13, 318-327.	0.3	8
225	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Molecular Cancer Therapeutics, 2020, 19, 2210-2220.	1.9	8
226	Multiple instance learning combined with label invariant synthetic data for guiding systematic prostate biopsy: a feasibility study. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 1023-1031.	1.7	8
227	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Canadian Urological Association Journal, 2020, 14, E373-E382.	0.3	8
228	S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.. Journal of Clinical Oncology, 2018, 36, TPS527-TPS527.	0.8	8
229	Second-opinion reads in prostate MRI: added value of subspecialty interpretation and review at multidisciplinary rounds. Abdominal Radiology, 2022, 47, 827-837.	1.0	8
230	Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs, 2007, 12, 435-448.	1.0	7
231	Recovery kinetics of heart rate and oxygen uptake in long-term survivors of acute leukemia in childhood. European Journal of Pediatrics, 2007, 166, 1135-1142.	1.3	7
232	Management of Advanced Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. Canadian Urological Association Journal, 2013, 7, 238.	0.3	7
233	Perioperative chemotherapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 3, 223.	0.3	7
234	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 458.e1-458.e7.	0.8	7

#	ARTICLE	IF	CITATIONS
235	Seeking the Molecular Truth in Bladder Cancer: Biology = Genome + (Transcriptome) 2. <i>European Urology</i> , 2017, 72, 366-367.	0.9	7
236	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E424-E460.	0.3	7
237	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 301.e17-301.e28.	0.8	7
238	A System for MR-Ultrasound Guidance during Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Lecture Notes in Computer Science</i> , 2015, , 497-504.	1.0	7
239	A 2D-3D Registration Framework for Freehand TRUS-Guided Prostate Biopsy. <i>Lecture Notes in Computer Science</i> , 2015, , 272-279.	1.0	7
240	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. <i>Canadian Urological Association Journal</i> , 2012, 6, 455-62.	0.3	7
241	Predicting occult lymph node-positive disease at the time of radical cystectomy: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016, 68, 112-24.	3.9	7
242	Demographic analysis of randomized controlled trials in bladder cancer. <i>BJU International</i> , 2013, 111, 419-426.	1.3	6
243	Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2013, 7, 306.	0.3	6
244	There is no role for focal therapy in prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 331.	0.3	6
245	Malakoplakia of the prostate masquerading as locally advanced prostate cancer on mpMRI. <i>Canadian Urological Association Journal</i> , 2015, 9, 910.	0.3	6
246	Chemical vs Surgical ADT in Metastatic Prostate Cancer: A Comparison of Side Effects. Commentary on Comparison of Gonadotropin-releasing Hormone Agonists and Orchiectomy: Effects of Androgen Deprivation Therapy. <i>Urology</i> , 2016, 93, 3-4.	0.5	6
247	Fine-tuning Risk Stratification for Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2016, 69, 70-71.	0.9	6
248	Evolving concepts in muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 1-2.	1.2	6
249	Expanding Immunotherapy Options for Bladder Cancer. <i>Urology</i> , 2017, 106, 1-2.	0.5	6
250	Perspectives on the discovery of NOTCH2-specific inhibitors. <i>Chemical Biology and Drug Design</i> , 2018, 91, 691-706.	1.5	6
251	A risk-stratified approach to the management of high-grade T1 bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 563-569.	0.9	6
252	Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1760-1762.	0.8	6

#	ARTICLE	IF	CITATIONS
253	Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy. <i>Nature Communications</i> , 2021, 12, 4833.	5.8	6
254	1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. <i>Journal of Urology</i> , 2007, 177, 502-502.	0.2	6
255	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. <i>Canadian Urological Association Journal</i> , 2016, 10, 90.	0.3	6
256	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2018, 12, 270-275.	0.3	6
257	Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. <i>European Urology Oncology</i> , 2022, 5, 677-686.	2.6	6
258	Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?. <i>Journal of Urology</i> , 2008, 180, 1146-1153.	0.2	5
259	Interference Cancellation Techniques for CDMA2000 1x Reverse Link. , 2009, , .		5
260	Three primary testicular tumours: Trials and tribulations of testicular preservation. <i>Canadian Urological Association Journal</i> , 2013, 7, 630.	0.3	5
261	Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 66.e13-66.e19.	0.8	5
262	Re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. <i>Eur Urol</i> 2015;68:399-405. <i>European Urology</i> , 2016, 69, e35.	0.9	5
263	Evolving attitudes toward robotic surgery among Canadian urology residents. <i>Canadian Urological Association Journal</i> , 2017, 11, E266-70.	0.3	5
264	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 429-440.	0.2	5
265	Magnet Before the Needle Commentary on: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis (PRECISION Trial). <i>Urology</i> , 2018, 118, 1-2.	0.5	5
266	Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery After Surgery (ERAS) program. <i>Canadian Urological Association Journal</i> , 2020, 15, 33-39.	0.3	5
267	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , 2020, 6, 65.	2.0	5
268	Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. <i>Pathology Research and Practice</i> , 2020, 216, 152822.	1.0	5
269	Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.. <i>Journal of Clinical Oncology</i> , 2018, 36, 569-569.	0.8	5
270	Towards targeted ultrasound-guided prostate biopsy by incorporating model and label uncertainty in cancer detection. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2022, 17, 121-128.	1.7	5

#	ARTICLE	IF	CITATIONS
271	Minimalist approach: functional mapping. <i>Clinical Neurosurgery</i> , 2002, 49, 90-102.	0.2	5
272	Renovascular Hypertension after Laparoscopic Partial Nephrectomy. <i>Journal of Urology</i> , 2014, 191, 1418-1420.	0.2	4
273	Pioglitazone: No Longer a Worry for Bladder Cancer?. <i>Urology</i> , 2016, 91, 19-20.	0.5	4
274	Achieving the "œtrifecta" with open versus minimally invasive partial nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 1569-1575.	1.2	4
275	Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. <i>European Urology Focus</i> , 2022, 8, 1256-1269.	1.6	4
276	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
277	A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 286-286.	0.8	4
278	Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4512-4512.	0.8	4
279	S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4591-TPS4591.	0.8	4
280	Uncertainty-Aware Deep Ensemble Model For Targeted Ultrasound-Guided Prostate Biopsy. , 2022, , .		4
281	Endogenous growth inhibition of angiogenesis in brain tumors. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 469-479.	2.7	3
282	MP28-14 TARGETING HER2 WITH TRASTUZUMAB-DM1 (T-DM1) IN HER2-OVEREXPRESSING BLADDER CANCER. <i>Journal of Urology</i> , 2014, 191, .	0.2	3
283	Multimodal classification of prostate tissue: a feasibility study on combining multiparametric MRI and ultrasound. <i>Proceedings of SPIE</i> , 2015, , .	0.8	3
284	Building the Case for Adjuvant Chemotherapy After Radical Cystectomy. <i>Urology</i> , 2016, 94, 1-2.	0.5	3
285	PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI). <i>Journal of Urology</i> , 2016, 195, .	0.2	3
286	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016, 34, 695-701.	1.2	3
287	New research in bladder cancer, ASCO-GU 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 160.	0.3	3
288	Has the Age of Cytoreductive Nephrectomy Come to an End?. <i>Urology</i> , 2018, 121, 1-2.	0.5	3

#	ARTICLE	IF	CITATIONS
289	Molecular landscape of carcinoma invading bladder muscle: does patient age matter?. BJU International, 2019, 124, 719-721.	1.3	3
290	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.3	3
291	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	0.9	3
292	Setting the stage for bladder preservation. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 209-212.	0.8	3
293	Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment. Bladder Cancer, 2021, 7, 1-11.	0.2	3
294	Characterizing The Uncertainty Of Label Noise In Systematic Ultrasound-Guided Prostate Biopsy. , 2021, , .		3
295	Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 498.e1-498.e11.	0.8	3
296	Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population.. Journal of Clinical Oncology, 2012, 30, 175-175.	0.8	3
297	Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa).. Journal of Clinical Oncology, 2014, 32, 298-298.	0.8	3
298	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 457-457.	0.8	3
299	A standardized protocol for identifying and counting lymph nodes harvested by pelvic lymph node dissection at the time of radical cystectomy. Canadian Urological Association Journal, 2015, 9, 337.	0.3	3
300	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. Central European Journal of Urology, 2020, 73, 407-415.	0.2	3
301	Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. Scientific Reports, 2022, 12, .	1.6	3
302	1080 A PROSPECTIVE RANDOMIZED TRIAL OF POVIDONE-IODINE PROPHYLACTIC CLEANSING OF THE RECTUM PRIOR TO TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY. Journal of Urology, 2012, 187, .	0.2	2
303	2130 VALIDATION OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH HIGH RISK PATHOLOGICAL FEATURES POST-PROSTATECTOMY. Journal of Urology, 2013, 189, .	0.2	2
304	Commentary on: Quality-of-Life Effects of Prostate-Specific Antigen Screening. Urology, 2013, 81, 7-8.	0.5	2
305	Comorbidity Status Does Not Independently Predict Survival Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2013, 64, 518-519.	0.9	2
306	Double jeopardy? Renal sparing management of simultaneous ipsilateral renal cell carcinoma and urothelial carcinoma. Canadian Urological Association Journal, 2013, 7, 508.	0.3	2

#	ARTICLE	IF	CITATIONS
307	Re: GÃ¼nter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland, Peter Albers. Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? Eur Urol 2013;64:355â€“7. European Urology, 2014, 65, e8-e9.	0.9	2
308	Bladder Tumor Resection: Doing it Right. Journal of Urology, 2014, 191, 1646-1647.	0.2	2
309	Radical Prostatectomy Trumps Watchful Waiting in Early Prostate Cancer Commentary on: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. Urology, 2014, 84, 253-254.	0.5	2
310	Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Research Notes, 2016, 9, 454.	0.6	2
311	Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. Urology, 2016, 89, 10-11.	0.5	2
312	Outcomes of Magnetic Resonance Imagingâ€“Ultrasound Fusion Prostate Biopsy of PI-RADS 3, 4, and 5 Lesions. Canadian Association of Radiologists Journal, 2018, 69, 303-310.	1.1	2
313	SIUâ€“ICUD consultation on bladder cancer 2018. World Journal of Urology, 2019, 37, 1-2.	1.2	2
314	Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. Computers in Biology and Medicine, 2020, 127, 104053.	3.9	2
315	Current Perioperative Therapy for Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 495-511.	0.9	2
316	The neoadjuvant management of muscle-invasive bladder cancer (MIBC) in Canada: A national survey of urologists.. Journal of Clinical Oncology, 2012, 30, 303-303.	0.8	2
317	Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database.. Journal of Clinical Oncology, 2014, 32, 420-420.	0.8	2
318	Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).. Journal of Clinical Oncology, 2016, 34, 223-223.	0.8	2
319	A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype.. Journal of Clinical Oncology, 2018, 36, 440-440.	0.8	2
320	Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 397-403.	1.4	2
321	485 MULTI-INSTITUTIONAL QUALITY OF CARE INITIATIVE FOR NON-METASTATIC MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER: PHASE 1. Journal of Urology, 2011, 185, .	0.2	1
322	Commentary on: Radical Prostatectomy Versus Observation for Localized Prostate Cancer. Urology, 2012, 80, 1181-1182.	0.5	1
323	594 SPECIFIC INHIBITON OF NOTCH-2 AS A NOVEL THERAPY FOR INVASIVE BLADDER CANCER. Journal of Urology, 2013, 189, .	0.2	1
324	2239 CLINICAL AND GENOMIC ANALYSIS OF METASTATIC DISEASE PROGRESSION IN A BACKGROUND OF BIOCHEMICAL RECURRENCE. Journal of Urology, 2013, 189, .	0.2	1

#	ARTICLE	IF	CITATIONS
325	MP64-06 RECURRENCE AND SURVIVAL AFTER PARTIAL VERSUS RADICAL NEPHRECTOMY FOR T1 RENAL MASS. Journal of Urology, 2014, 191, .	0.2	1
326	MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2014, 191, .	0.2	1
327	Prostate-specific Antigen Testing: Men's Responses to 2012 Recommendation Against Screening. Urology, 2014, 83, 4-5.	0.5	1
328	Motion and deformation compensation for freehand prostate biopsies. , 2014, , .		1
329	MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY. Journal of Urology, 2015, 193, .	0.2	1
330	Taking the next step"Advancing bladder cancer management. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 435-436.	0.8	1
331	Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial. Urology, 2017, 104, 7-8.	0.5	1
332	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. CMAJ Open, 2017, 5, E834-E841.	1.1	1
333	Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 403-404.	0.8	1
334	Immune system trickery and deception: Allograft-derived neuroendocrine carcinoma post kidney transplantation. Urology Case Reports, 2018, 21, 89-91.	0.1	1
335	Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?. European Urology Oncology, 2019, 2, 723-729.	2.6	1
336	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer, 2020, 6, 363-392.	0.2	1
337	1647: Differences in Survival Between Patients with Sarcomatoid Carcinoma, Carcinosarcoma and Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2007, 177, 546-546.	0.2	1
338	Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.. Journal of Clinical Oncology, 2012, 30, 90-90.	0.8	1
339	NOTCH2 inhibition on tumor growth and metastasis in bladder cancer.. Journal of Clinical Oncology, 2014, 32, 315-315.	0.8	1
340	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2016, 34, 393-393.	0.8	1
341	Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.. Journal of Clinical Oncology, 2019, 37, e16036-e16036.	0.8	1
342	Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.. Journal of Clinical Oncology, 2019, 37, 526-526.	0.8	1

#	ARTICLE	IF	CITATIONS
343	Utilization of local salvage therapy after primary radiotherapy for prostate cancer.. Journal of Clinical Oncology, 2013, 31, 231-231.	0.8	1
344	Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.. Journal of Clinical Oncology, 2013, 31, 36-36.	0.8	1
345	Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience.. Journal of Clinical Oncology, 2014, 32, 434-434.	0.8	1
346	The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis.. Journal of Clinical Oncology, 2015, 33, 480-480.	0.8	1
347	Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. Journal of Clinical Oncology, 2016, 34, e23075-e23075.	0.8	1
348	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.3	1
349	RETRACTILE MESENTERITIS MIMICKING AN ADRENAL TUMOR. Journal of Urology, 1999, 162, 1677-1678.	0.2	0
350	Fournier's Gangrene. , 2005, , 157-168.		0
351	Re: Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. European Urology, 2007, 51, 1140-1141.	0.9	0
352	RACIAL VARIATION IN THE MATRIX METALLOPROTEINASE: E-CADHERIN RATIO IN LOCALIZED PROSTATE CANCER: RESULTS FROM A CONTEMPORARY MATCHED COMPARATIVE STUDY. Journal of Urology, 2008, 179, 421-422.	0.2	0
353	E-CADHERIN EXPRESSION POTENTIATES ERLOTINIB TREATMENT IN BLADDER CANCER. Journal of Urology, 2008, 179, 372-372.	0.2	0
354	A NOVEL ACTIVATOR OF THE ORPHAN NUCLEAR RECEPTOR Nurr1 INHIBITS BLADDER TUMOR GROWTH. Journal of Urology, 2008, 179, 369-369.	0.2	0
355	774 DIFFERENTIAL EXPRESSION OF NOTCH-1 AND NOTCH-2 CORRELATES TO INVASIVE PHENOTYPE IN BLADDER CANCER CELL LINES. Journal of Urology, 2010, 183, .	0.2	0
356	363 ABERRANT SONIC HEDGEHOG SIGNALING IN RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.2	0
357	2130 BACTERIAL GROWTH IN THE RECTUM AND URINE BEFORE AND AFTER TRANS-RECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY. Journal of Urology, 2011, 185, .	0.2	0
358	1363 TARGETING FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)-3 IN BLADDER CANCER: PRE-CLINICAL PROOF OF PRINCIPLE. Journal of Urology, 2011, 185, .	0.2	0
359	The Canadian Bladder Cancer Network: efforts to improve patient care. Canadian Urological Association Journal, 2011, 5, 88-88.	0.3	0
360	641 MANAGEMENT OF THE INTRAVESICAL URETER AND BLADDER CLIFF DURING RADICAL NEPHROURETERECTOMY: OUTCOMES FROM THE CANADIAN UPPER TRACT COLLABORATION. Journal of Urology, 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
361	1065 INFLUENCE OF RESISTANCE TO GEMCITABINE AND CISPLATIN ON TUMOR GROWTH, ADHESIVE AND INVASIVE PROPERTIES IN CHEMORESISTANT BLADDER CANCER CELL LINES. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
362	1479 CLINICALLY SIGNIFICANT URETHRAL STRICTURE AND/OR SUBCLINICAL URETHRAL STRICTURE AFTER HIGH-INTENSITY FOCUSED ULTRASOUND PARADOXICALLY CORRELATES WITH DISEASE-FREE SURVIVAL IN LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
363	Commentary on: Everolimus for Angiomyolipoma Associated With Tuberous Sclerosis Complex or Sporadic Lymphangiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-blind, Placebo-controlled Trial. <i>Urology</i> , 2013, 82, 278-279.	0.5	0
364	1125 SILENCING NOTCH-1 AND NOTCH-3 PROMOTES EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) AND SELF-RENEWAL POTENTIAL IN HUMAN BLADDER CANCER. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
365	1492 BIOCHEMICAL PROGRESSION FREE SURVIVAL AFTER RADICAL PROSTATECTOMY IN MEN WITH HIGH-RISK CLINICALLY LOCALISED PROSTATE CANCER. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
366	Radical Locoregional Therapy for Bladder Cancer: Underutilized, or Unsuitable in Many?. <i>European Urology</i> , 2013, 63, 830-831.	0.9	0
367	Intermittent Versus Continuous Androgen Deprivation in Prostate Cancer. <i>Urology</i> , 2013, 82, 985-986.	0.5	0
368	Commentary on: Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. <i>Urology</i> , 2013, 81, 473-474.	0.5	0
369	592 ULTRASOUND-GUIDED INTRAMURAL INOCULATION OF ORTHOTOPIC BLADDER CANCER XENOGRAFTS. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
370	1066 TSPAN8 EXPRESSION IN RENAL CELL CARCINOMA IS A POOR PROGNOSTIC FACTOR AND A NOVEL THERAPEUTIC TARGET. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
371	Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. <i>Urology</i> , 2013, 81, 1121-1122.	0.5	0
372	Using clinical practice guidelines in our own backyard: treating our patients with bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 268.	0.3	0
373	MP39-09 A COMBINATION OF GENOMIC MARKERS AND CLINICAL VARIABLES PROVIDES SUPERIOR PROGNOSTIC PERFORMANCE IN HIGH-RISK BLADDER CANCER FOLLOWING CYSTECTOMY. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
374	MP57-18 SHORT-TERM OUTCOME OF METASTASECTOMY IN RENAL CELL CARCINOMA: THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM INITIAL EXPERIENCE.. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
375	MP37-17 INTRAOPERATIVE REGISTERED TRANSRECTAL ULTRASOUND GUIDANCE FOR ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY: A 20 PATIENT STUDY. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
376	MP67-12 MRI TARGETED BIOPSY FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS AFTER PRIOR NEGATIVE BIOPSIES.. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
377	A New Way of Thinking About Bladder Cancer. <i>Urology</i> , 2014, 84, 1265-1266.	0.5	0
378	MP40-02 INCREASED UPTAKE OF RENAL TUMOUR BIOPSIES FOR SMALL RENAL MASSES – RESULTS OF A MULTICENTRE CANADIAN EXPERIENCE. <i>Journal of Urology</i> , 2014, 191, .	0.2	0

#	ARTICLE	IF	CITATIONS
379	PD12-03 ACTIVE SURVEILLANCE IN 853 MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
380	PD17-11 POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: PREDICTORS AND IMPACT ON ONCOLOGICAL OUTCOMES. Journal of Urology, 2014, 191, .	0.2	0
381	MP61-02 BALANCING ONCOLOGIC BENEFIT WITH RISK OF COMPLICATIONS: THE EXTENT PELVIC LYMPH NODE DISSECTION DURING RADICAL CYSTECTOMY.. Journal of Urology, 2014, 191, .	0.2	0
382	MP62-09 COMPARISON OF PATHOLOGICAL AND ONCOLOGICAL OUTCOMES OF MEN ON ACTIVE SURVEILLANCE PROGRESSING TO RADICAL PROSTATECTOMY WITH A MATCHED COHORT OF MEN UNDERGOING IMMEDIATE RADICAL PROSTATECTOMY IN A SINGLE INSTITUTION. Journal of Urology, 2014, 191, .	0.2	0
383	MP51-20 MULTI-PARAMETRIC MRI ENHANCES DETECTION OF SIGNIFICANT TUMOR IN PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
384	PD10-12 CLINICAL OUTCOMES FOLLOWING LAPAROSCOPIC MANAGEMENT OF PT3 RENAL MASSES: A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
385	MP59-16 RENAL ARTERY PSEUDOANEURYSMS AFTER NEPHRON SPARING SURGERY FOR RENAL CELL CARCINOMA: INCIDENCE, MANAGEMENT AND FUNCTIONAL OUTCOMES FROM CANADIAN KIDNEY CANCER INFORMATION SYSTEM DATABASE.. Journal of Urology, 2014, 191, .	0.2	0
386	MP1-07 ENRICHMENT OF CIRCULATING TUMOR CELLS IN PATIENTS WITH LOCALIZED PROSTATE CANCER USING A MICROFLUIDIC DEVICE. Journal of Urology, 2015, 193, .	0.2	0
387	MP57-20 VARIANT HISTOLOGY DOES NOT PREDICT SURVIVAL OUTCOMES AFTER RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE CANADIAN UPPER TRACT COLLABORATION. Journal of Urology, 2015, 193, .	0.2	0
388	PD41-05 FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PTO PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1?. Journal of Urology, 2015, 193, .	0.2	0
389	MP77-01 NATURAL HISTORY OF PROSTATIC LESIONS ON SERIAL MULTIPARAMETRIC MRI.. Journal of Urology, 2015, 193, .	0.2	0
390	MP72-15 THE INTERVAL BETWEEN DIAGNOSIS AND RADICAL CYSTECTOMY DOES NOT IMPACT THE OUTCOMES OF PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY. Journal of Urology, 2015, 193, .	0.2	0
391	MP84-08 PATHOLOGICAL UPSTAGING OF CLINICAL T1 RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES. Journal of Urology, 2015, 193, .	0.2	0
392	PD31-09 CLINICAL FACTORS PREDICTING PATHOLOGICAL POSITIVE LYMPH NODES IN CLINICALLY NODE NEGATIVE PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY. Journal of Urology, 2015, 193, .	0.2	0
393	PD41-08 CAN BLADDER CANCER GENE EXPRESSION SIGNATURES BE USED TO PREDICT LYMPH NODE METASTASIS AT THE TIME OF RADICAL CYSTECTOMY?. Journal of Urology, 2015, 193, .	0.2	0
394	Reply. Urology, 2015, 85, 429.	0.5	0
395	MP49-09 ACTIVATION OF IFN/STAT1 SIGNALING IN CISPLATIN/GEMCITABINE RESISTANT BLADDER CANCER. Journal of Urology, 2015, 193, .	0.2	0
396	MP49-13 LIM-SH3 DOMAIN PROTEIN 1 KNOCKDOWN INHIBITS CELL GROWTH AND ENHANCES ACTIVITY OF CISPLATIN IN BLADDER CANCER.. Journal of Urology, 2015, 193, .	0.2	0

#	ARTICLE	IF	CITATIONS
397	PD27-09 INCIDENCE AND SIGNIFICANCE OF THROMBO-EMBOLIC EVENTS IN BLADDER UROTHELIAL CARCINOMA PATIENTS UNDERGOING NEO-ADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY: RESULTS FROM MULTI-CENTRE NORTH-AMERICAN AND EUROPEAN CONTEMPORARY DATA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
398	PD03-06 RADICAL PROSTATECTOMY FOLLOWING ACTIVE SURVEILLANCE IS ASSOCIATED WITH INCREASED RATES OF UNFAVOURABLE PATHOLOGY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
399	MP49-01 NEXT GENERATION SEQUENCING OF CELL FREE DNA REVEALS GENOMIC ABERRATIONS IN METASTATIC UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
400	MP61-03 EVALUATION OF LACTATE TRANSPORTERS AS POTENTIAL THERAPEUTIC TARGET IN UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
401	PD38-01 NOTCH2-HEY AXIS PROMOTES TUMOR GROWTH IN BLADDER CANCER THROUGH CELL CYCLE PROGRESSION AND DEDIFFERENTIATION. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
402	MP45-04 PATERNALLY EXPRESSED GENE-10 PROMOTES CELL GROWTH AND INVASION OF BLADDER CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
403	Comparison of Magnetic Resonance/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. <i>Urology</i> , 2016, 89, 6-7.	0.5	0
404	Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>European Urology</i> , 2016, 70, 1076.	0.9	0
405	MP01-17 ASSOCIATION OF DISTANCE TO TREATMENT FACILITY WITH SURVIVAL AND QUALITY OUTCOMES FOLLOWING RADICAL CYSTECTOMY: A MULTI-INSTITUTIONAL STUDY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
406	MP75-09 THE NATURAL HISTORY OF RENAL FUNCTION AFTER SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
407	MP13-20 SECOND-GENERATION ANTISENSE OLIGONUCLEOTIDE - HSP27 A NEW INTRAVESICAL TREATMENT FOR BLADDER CANCER: PHASE 1 CLINICAL TRIAL.. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
408	PD33-11 NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER: P53-NESS IS ASSOCIATED WITH CHEMO-RESISTANCE AND UNFAVORABLE OUTCOME. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
409	MP61-13 PROGRANULIN TARGETING IN UROTHELIAL CANCER CELLS INHIBITS MOTILITY, ANCHORAGE-INDEPENDENT GROWTH, TUMOR FORMATION IN VIVO AND SENSITIZES CELLS TO CISPLATIN. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
410	PD12-12 COMPLICATION RATES AFTER RADICAL CYSTECTOMY AFTER RADIOTHERAPY: AN INTERNATIONAL, MULTICENTER RETROSPECTIVE STUDY ON 609 CASES. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
411	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 215-215.	0.2	0
412	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 595-595.	0.2	0
413	Commentary on: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy. <i>Urology</i> , 2017, 105, 13.	0.5	0
414	MP34-05 THE PROGNOSTIC SIGNIFICANCE OF TNM STAGING IN BLADDER CANCER AFTER NEOADJUVANT CHEMOTHERAPY CAN BE ENHANCED WITH TUMOR REGRESSION GRADING. <i>Journal of Urology</i> , 2017, 197, .	0.2	0

#	ARTICLE	IF	CITATIONS
415	You Pays Your Money, You Takes Your Choice: Functional Outcomes Following Curative Treatment for Clinically Localized Prostate Cancer. <i>Urology</i> , 2017, 107, 3-4.	0.5	0
416	Commentary on: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>Urology</i> , 2017, 104, 5-6.	0.5	0
417	MP34-01 MOLECULAR SUBTYPES OF MUSCLE INVASIVE BLADDER CANCER ARE RELATED TO BENEFIT FROM NEOADJUVANT CHEMOTHERAPY: DEVELOPMENT OF A SINGLE SAMPLE PATIENT ASSAY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
418	MP44-08 THE LANDSCAPE OF HER2 ALTERATIONS IN MUSCLE-INVASIVE BLADDER CANCER: IMPACT ON PATIENT SELECTION FOR TARGETED THERAPIES?. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
419	MP65-03 INHIBITION OF PEG10 MAY BE A NOVEL TREATMENT STRATEGY FOR A SUBSET OF BLADDER CANCER.. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
420	MP04-07 PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL CLASSIFICATION OF BLADDER CANCER ACCORDING TO LUMINAL (UROPLAKIN III) AND BASAL (CYTOKERATIN 5/6) MARKERS. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
421	MP98-03 T-DM1, A NOVEL HER2 ANTIBODY-CYTOTOXIC DRUG CONJUGATE, HAS ANTI-METASTATIC POTENTIAL AND IS EFFECTIVE IN BLADDER CANCER WITH HER2 IHC SCORE 2+/3+. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
422	Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer. <i>Urology</i> , 2017, 109, 1-2.	0.5	0
423	Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma. <i>European Urology</i> , 2017, 72, 653-654.	0.9	0
424	Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. <i>Urology</i> , 2018, 116, 1-2.	0.5	0
425	Critical Questions To Optimize Intravesical Therapy for Non-“muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018, 4, 463.	1.6	0
426	New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. <i>Bladder Cancer</i> , 2018, 4, 339-342.	0.2	0
427	Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 815-817.	0.8	0
428	Hope, hype and biology: the current biomarker landscape in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 1739-1740.	1.2	0
429	Editorial: Basic research in bladder cancer “refining the tools. 3rd IBCN seminars series1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 855-857.	0.8	0
430	Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2020, 15, E123-E126.	0.3	0
431	Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>Eur Urol</i> 2020;78:907-915. <i>European Urology</i> , 2021, 79, e182-e183.	0.9	0
432	Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	0

#	ARTICLE	IF	CITATIONS
433	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 528-547.	0.8	0
434	Abstract 3065: Loss of ARL11 function promotes growth of in situ neoplasia by activating the ras pathway. , 2010, , .		0
435	Abstract 234: Fibroblast growth factor receptor (FGFR)-3 as a suitable target in bladder cancer. , 2011, , .		0
436	Improving outcomes through the development of quality indicators in renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 422-422.	0.8	0
437	The impact of time to metastasis on survival in treatment-naïve prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 212-212.	0.8	0
438	Patient perceptions of ovarian cancer, its treatment, and its impact: A qualitative interview study in three European countries.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16550-e16550.	0.8	0
439	Canadian guidelines for SRMs: How Canadian are they?. <i>Canadian Urological Association Journal</i> , 2015, 9, 163.	0.3	0
440	Successful implementation of a disease-specific survivorship program for men with prostate cancer (PC) and their partners.. <i>Journal of Clinical Oncology</i> , 2016, 34, 31-31.	0.8	0
441	Implementation of a disease specific survivorship program for men with prostate cancer and their partners.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21569-e21569.	0.8	0
442	Abstract 5191: An orthotopic xenograft renal cell carcinoma Sunitinib resistant murine model. , 2016, , .		0
443	Abstract 3798: A glycan-binding malaria protein provides therapeutic access to cisplatin-resistant bladder cancer. , 2016, , .		0
444	Abstract 698: Progranulin targeting in urothelial cancer cells inhibits motility, tumor growth in vitro and in vivo and sensitizes cells to cisplatin. , 2016, , .		0
445	Abstract B103: Intravesical administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy. , 2016, , .		0
446	Abstract 5397: Characterizing the genomic landscape of bladder cancer with circulating tumor DNA. , 2017, , .		0
447	Apparent plasticity in the biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 433-433.	0.8	0
448	Patterns and predictors of attendance at a comprehensive, multi-disciplinary supportive care program for men with prostate cancer and their partners.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6-6.	0.8	0
449	Abstract 3689: Identification of candidate therapeutic targets in BCG unresponsive bladder cancer-inflammatory subtypes of BCG unresponsive bladder cancer. , 2018, , .		0
450	Re: Clinical Efficacy and Biomarker Analysis of Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial. <i>European Urology</i> , 2020, 77, 652-653.	0.9	0

#	ARTICLE	IF	CITATIONS
451	Not “self”, but “When” and “How”: Testing Antibody-Drug Conjugates in Patients with Non-“muscle-invasive Bladder Cancer. European Urology, 2021, 81, 143-143.	0.9	0
452	Establishing a Foundation for Studying the Immune Contexture Across the Spectrum of Bladder Cancer. European Urology Oncology, 2022, , .	2.6	0